## Steven L Taylor

## List of Publications by Citations

Source: https://exaly.com/author-pdf/9268033/steven-l-taylor-publications-by-citations.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29 912 13 30 h-index g-index citations papers 1,276 4.13 32 7.7 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
29	Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2017</b> , 390, 659-668	40	348
28	Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 141, 94-103.e15	11.5	159
27	Long-Term Azithromycin Reduces and Increases Antibiotic Resistance in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 309-317	10.2	70
26	Matrix metalloproteinases vary with airway microbiota composition and lung function in non-cystic fibrosis bronchiectasis. <i>Annals of the American Thoracic Society</i> , <b>2015</b> , 12, 701-7	4.7	57
25	Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. <i>Lancet Respiratory Medicine,the</i> , <b>2019</b> , 7, 845-854	35.1	51
24	Host-microbiome interactions in acute and chronic respiratory infections. <i>Cellular Microbiology</i> , <b>2016</b> , 18, 652-62	3.9	29
23	Impact of Long-Term Erythromycin Therapy on the Oropharyngeal Microbiome and Resistance Gene Reservoir in Non-Cystic Fibrosis Bronchiectasis. <i>MSphere</i> , <b>2018</b> , 3,	5	28
22	Infection Sweet Tooth: How Glycans Mediate Infection and Disease Susceptibility. <i>Trends in Microbiology</i> , <b>2018</b> , 26, 92-101	12.4	27
21	genotype influences lung function, exacerbation frequency and airway microbiota in non-CF bronchiectasis. <i>Thorax</i> , <b>2017</b> , 72, 304-310	7:3	24
20	Macrolide Treatment Inhibits Pseudomonas aeruginosa Quorum Sensing in Non-Cystic Fibrosis Bronchiectasis. An Analysis from the Bronchiectasis and Low-Dose Erythromycin Study Trial. <i>Annals of the American Thoracic Society</i> , <b>2016</b> , 13, 1697-1703	4.7	20
19	Airway abundance of predicts response to azithromycin in adults with persistent uncontrolled asthma. <i>European Respiratory Journal</i> , <b>2020</b> , 56,	13.6	16
18	The impact of CFTR modulator therapies on CF airway microbiology. <i>Journal of Cystic Fibrosis</i> , <b>2020</b> , 19, 359-364	4.1	15
17	Neutrophils in asthma: the good, the bad and the bacteria. <i>Thorax</i> , <b>2021</b> ,	7:3	15
16	Understanding the impact of antibiotic therapies on the respiratory tract resistome: a novel pooled-template metagenomic sequencing strategy. <i>Multidisciplinary Respiratory Medicine</i> , <b>2018</b> , 13, 30	3	11
15	is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease. <i>European Respiratory Journal</i> , <b>2021</b> ,	13.6	11
14	Total bacterial load, inflammation, and structural lung disease in paediatric cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , <b>2020</b> , 19, 923-930	4.1	6
13	The contribution of respiratory microbiome analysis to a treatable traits model of care. <i>Respirology</i> , <b>2019</b> , 24, 19-28	3.6	6

## LIST OF PUBLICATIONS

12	Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy. <i>Thorax</i> , <b>2021</b> , 76, 733-736	7.3	4	
11	Intestinal Microbiota Composition in Sudden Infant Death Syndrome and Age-Matched Controls. <i>Journal of Pediatrics</i> , <b>2017</b> , 191, 63-68.e1	3.6	3	
10	Prevention of SARS-CoV-2 (COVID-19) transmission in residential aged care using ultraviolet light (PETRA): a two-arm crossover randomised controlled trial protocol. <i>BMC Infectious Diseases</i> , <b>2021</b> , 21, 967	4	3	
9	Conventional myelosuppressive chemotherapy for non-haematological malignancy disrupts the intestinal microbiome. <i>BMC Cancer</i> , <b>2021</b> , 21, 591	4.8	2	
8	The influence of early-life microbial exposures on long-term respiratory health. <i>Paediatric Respiratory Reviews</i> , <b>2021</b> , 40, 15-23	4.8	2	
7	The effects of increasing fruit and vegetable intake in children with asthma: A randomized controlled trial. <i>Clinical and Experimental Allergy</i> , <b>2021</b> , 51, 1144-1156	4.1	2	
6	PPARIIs reduced in the airways of non-CF bronchiectasis subjects and is inversely correlated with the presence of Pseudomonas aeruginosa. <i>PLoS ONE</i> , <b>2018</b> , 13, e0202296	3.7	1	
5	Intestinal microbiology shapes population health impacts of diet and lifestyle risk exposures in Torres Strait Islander communities. <i>ELife</i> , <b>2020</b> , 9,	8.9	1	
4	Ear microbiota and middle ear disease: a longitudinal pilot study of Aboriginal children in a remote south Australian setting <i>BMC Microbiology</i> , <b>2022</b> , 22, 24	4.5	O	
3	Investigating potential transmission of antimicrobial resistance in an open-plan hospital ward: a cross-sectional metagenomic study of resistome dispersion in a lower middle-income setting.  Antimicrobial Resistance and Infection Control, 2021, 10, 56	6.2	О	
2	The cystic fibrosis gut as a potential source of multidrug resistant pathogens. <i>Journal of Cystic Fibrosis</i> , <b>2021</b> , 20, 413-420	4.1	О	
1	Assessment of Long-Term Macrolide Exposure on the Oropharyngeal Microbiome and Macrolide Resistance in Healthy Adults and Consequences for Onward Transmission of Resistance  Antimicrobial Agents and Chemotherapy. 2022. e0224621	5.9	О	